Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

47.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceu

< Previous 1 2 3 4 5 6 7 8 Next >
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
Via Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: 
Via Benzinga
Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at Piper Sandler Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Departure of Chief Financial Officer
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at Upcoming Healthcare Conferences
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 283 companies set new 52-week lows. 
Via Benzinga
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Earnings Scheduled For November 2, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 265 companies made new 52-week lows. 
Via Benzinga
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
Gainers 
Via Benzinga
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Wolfspeed, Inc. (NYSE: WOLF) rose 20.7% to $103.40 in pre-market trading after the company reported better-than-expected Q4 results. 
Via Benzinga
NVIDIA, Tyson Foods, BioNTech And Some Other Big Stocks Moving Lower On Monday
  AMTD Digital Inc. (NYSE: HKD) dipped 21.8% to $563.71 on possible profit taking after the stock surged over the last few trading days. 
Via Benzinga
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: 
Via Benzinga
Recap: Ultragenyx Pharmaceutical Q2 Earnings
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.